The effect of low-dose colchicine on cause-specific mortality in the LoDoCo2 trial

T.S.J Opstal,S.M Nidorf,A.T.L Fiolet,J.W Eikelboom,A Mosterd,P.L Thompson,C Budgeon,J.G.P Tijssen,W.A Bax,J.H Cornel

doi:10.1016/j.atherosclerosis.2021.06.100

The effect of low-dose colchicine on cause-specific mortality in the LoDoCo2 trial

T.S.J Opstal, S.M Nidorf + Show 8 more

https://doi.org/10.1016/j.atherosclerosis.2021.06.100

Copy DOI

Journal: Atherosclerosis

Publication Date: Aug 1, 2021

Affiliation: McMaster University, Werkgroep Cardiologische centra Nederland, Meander Medisch Centrum, Western University, University of Western Australia, University of Amsterdam

#Cause-specific Mortality #Cardiovascular Events In Patients + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background and Aims: Low-dose colchicine significantly reduces non-fatal cardiovascular events in patients with chronic coronary disease, but effects on mortality are ambiguous. Deeper insight into cause-specific mortality could address safety concerns on colchicine and fatalities.

Full Text